Navigation Links
PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
Date:9/8/2008

actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including ClinPhone; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the Fiscal Year ended June 30, 2008 as filed with the SEC on August 28, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward- looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
2. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
3. PAREXEL Closes the Acquisition of ClinPhone
4. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
5. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
6. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
7. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
8. PAREXEL Expands Global Clinical Logistics Capabilities
9. Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 2008
10. PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
11. PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015  PDS Biotechnology Corp. announces preliminary ... targeting HPV-16, has generated strong T-cell responses in ... cancer is treated by surgical removal of lesions ... non-surgical alternative. Results show that it primes and ... target, and kill precancerous and cancerous cells that ...
(Date:5/28/2015)... 28, 2015 Biscayne Pharmaceuticals, Inc ., ... its growth hormone-releasing hormone (GHRH) technology will be discussed in ... Annual Meeting. The data show that the family of ... blockers, is present on many primary breast cancer cells ... GHRH antagonists could have broad anti-cancer potential in breast ...
(Date:5/28/2015)... and London (PRWEB) May 28, 2015 ... of Computer Aided Engineering software, announced today it ... Inc. (PSRI). CD-adapco will provide state-of-the-art engineering simulation ... will share their expertise and experiences in analyzing ... refining industry members and advance the understanding of ...
(Date:5/28/2015)... May 28, 2015 Glenn Keet, CEO ... Changing Landscape of EMR/EHR Clinical Data Integration with EDC ... place in Washington, DC on June 14th-18th. , During ... integrating EMR/EHR systems with EDC, and will examine the ... by eSource and electronic health records/electronic medical records integration. ...
Breaking Biology Technology:PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2
... Researchers have identified the gene that ultimately controls ... could some day lead to the repair of damaged ... or even the production of replacement teeth. , The ... already known to have several functions - in immune ...
... Feb. 23 Texcel Medical, LLC, a full ... manufacturing company, has announced the appointment of ... all functions at Texcel Medical , which ... manufacturing infrastructure and expertise they need to accelerate ...
... Inc. announced,today that it has entered into a ... sodium for the intravenous treatment of pulmonary,arterial hypertension ... headquarters in Allschwil/Basel, Switzerland. Financial terms of the ... "This sale speaks directly to our company,s ongoing ...
Cached Biology Technology:Genetic discovery could lead to advances in dental treatment 2Texcel Medical Appoints Barry Smith as President, CEO 2GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd. 2GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd. 3
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, ... control and security systems is pleased to announce that ... as a consultant and member of its scientific advisory ... widely known as a thought leader in technology-enhanced learning ... Technology Group, and has published studies and books focused ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... have long been considered the kings of the horned ... further back in time, when a newly discovered species appears ... it the earliest known member of its family. ... myth of the Titans, rivaled Triceratops in size, ...
... mountaintop comes a new research report in the FASEB Journal ... happens to the hearts of people when exposed to low-levels of ... care unit of a hospital. In the study, researchers monitored subjects ... that the low-level oxygen conditions at the base came caused changes ...
... ants have a big impact on their local environment as ... The study, published in the Journal of Animal ... their local environment. Firstly, through moving of soil by ... level of nutrients in the soil. This can indirectly impact ...
Cached Biology News:Newly discovered dinosaur likely father of Triceratops 2Scientists climb Mt. Everest to explain how hearts adapt and recover from low oxygen 2Ants' ecosystem role is 'key' 2
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
Oxidative Stress-Inducible Protein Tyrosine Phosphatase...
... Large T antigen initiates replication ... replication in the presence of ... product can be used in ... Replication Kit cat. no. 8050. ...
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Biology Products: